drugset / Trial / NCT02440009

A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis

NCT02440009

RandomizedSingle-groupOpen-labelTreatment

Summary

The study evaluates the addition of itraconazole to glucocorticoids in management of acute stages of allergic bronchopulmonary aspergillosis (ABPA). Half of the participants will receive glucocorticoids while the other half will receive itraconazole and glucocorticoids

Timeline

Start
2014-05
Primary completion
2017-07
Completion
2017-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Background Prednisolone Other / unclassified 0.125 mg/kg Oral